Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020;7(1):71-83.
doi: 10.1007/s40521-020-00242-2. Epub 2020 Jan 18.

Hypersensitivity Reactions to Biologicals: from Bench to Bedside

Aysegul Akarsu  1 , Ozge Soyer  1 , Bulent Enis Sekerel  1
Affiliations
Review

Hypersensitivity Reactions to Biologicals: from Bench to Bedside

Aysegul Akarsu et al. Curr Treat Options Allergy. 2020.

Abstract

Purpose of review: Biologic agents are new treatment options for chronic inflammatory diseases and cancers. As a result of their unique mechanism of action, they are more effective and less toxic treatment option and their clinical usage is increasing. While they are more commonly used, various adverse effects have been observed including life-threatening ones, including anaphylaxis. The aim of this review is to distinguish the anaphylaxis from other hypersensitivity reactions (HSR) and provide a management algorithm for the anaphylactic reactions induced by biological agents.

Recent findings: Many case reports and series have been published regarding anaphylaxis and other hypersensitivity reactions (concerning cytokine release syndrome, acute infusion-related reactions) due to biologic agents. Although acute treatment of HSR varies according to the clinical presentation, desensitization with the drug is the major management option for subsequent administrations in the case of anaphylactic reactions.

Summary: Anaphylaxis and other immediate onset hypersensitivity reactions are occasionally difficult to differentiate from each other, and mixed-type reactions may be observed. Immediate management of anaphylaxis includes discontinuation of infusion, immediate administration of adrenaline, antihistamines, corticosteroids, and other treatment options depending on the symptoms. After 30-120 min of the reaction, a blood sample for serum tryptase levels should be obtained and after 4-6 weeks skin testing with the culprit drug should be performed for decision of long-term management via either graded challenge or desensitization.

Keywords: Anaphylaxis; Biologic agents; Hypersensitivity reactions; Monoclonal antibodies.

PubMed Disclaimer

Conflict of interest statement

Conflict of InterestAysegul Akarsu declares that he has no conflict of interest. Ozge Soyer declares that he has no conflict of interest. Bulent Enis Sekerel declares that he has no conflict of interest.

Figures

Fig. 1
Fig. 1
The algorithm for management of hypersensitivity reactions with biologics.
See this image and copyright information in PMC

References

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Alkan SS. Legends of allergy/immunology: Georges Kohler and the discovery of monoclonal antibodies. Allergy. 2019;74(7):1412–1414. doi: 10.1111/all.13798. - DOI - PubMed
    1. Li GN, Wang SP, Xue X, Qu XJ, Liu HP. Monoclonal antibody-related drugs for cancer therapy. Drug Discov Ther. 2013;7(5):178–184. - PubMed
    1. Approvals FaDAB, Year b. https://www.fda.gov/vaccines-blood-biologics/development-approval-proces.... Accessed 11/ 11 /2019.
    1. Hausmann OV, Seitz M, Villiger PM, Pichler WJ. The complex clinical picture of side effects to biologicals. Med Clin North Am. 2010;94(4):791–804. doi: 10.1016/j.mcna.2010.03.001. - DOI - PubMed
    1. https://www.who.int/medicines/services/inn/Revised_mAb_nomenclature_sche.... Revised monoclonal antibody (mAb) nomenclature scheme. Geneva, 26 May 2017.

LinkOut - more resources